# US 2004/0019093 A1 · Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019093 A1
- Document ID: US20040019093A1
- Status: Published application
- Kind: A1
- Application number: 10/425,210
- Filed: 2003-04-29
- Published: 2004-01-29
- Earliest claimed: 2002-04-30
- Inventors: Judith Aronhime; Sandor Molnar; Csaba Szabo; Erzsebet Meszaros Sos; Szabolcs Salyi; Tivadar Tamas
- Web page: https://patentgrep.com/patent/US20040019093A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 35/00: Antineoplastic agents
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Ondansetron crystalline Forms A and B are useful in the treatment of nausea and vomiting. Form B has a uniquely high melting point of about 244° C. and both forms are stable against thermally induced polymorphic transition from 30° C. up to their melting points.

## Claims

### Claim 1

A high melting crystalline form of ondansetron characterized by a thermal analysis result indicative of a melting point of 244±2° C.

### Claim 2 (depends on 1)

The crystalline form of ondansetron of claim 1 wherein the thermal analysis result is a differential scanning calorimetry thermogram taken at a heating rate of 10° C. min−1 in a closed pan that exhibits a melting endotherm with a maximum at 244±2° C.

### Claim 3 (depends on 2)

The crystalline form of ondansetron of claim 2 wherein the melting endotherm has a magnitude of 140±10 Joules per gram.

### Claim 4 (depends on 1)

The crystalline form of ondansetron of claim 1 further characterized by a powder X-ray diffraction pattern having peaks at 25.8, 26.9 and 28.1±1.0 degrees two-theta.

### Claim 5 (depends on 4)

The crystalline form of ondansetron of claim 4 further characterized by strong intensity peaks in the powder X-ray diffraction pattern at 15.9, 23.1, 23.5, 25.8, 26.9, and 28.1±1.0 degrees two-theta and medium intensity peaks at 25.8 and 26.9±1.0 degrees two-theta.

### Claim 6 (depends on 5)

The crystalline form of ondansetron of claim 5 further characterized by peaks in the powder X-ray diffraction pattern at 11.0, 14.9, 15.5, 16.5, 20.6, 21.4, 24.2±1.0 degrees two-theta.

### Claim 7 (depends on 1)

The crystalline form of ondansetron of claim 1 containing less than or equal to about 5% other crystalline forms of ondansetron.

### Claim 8 (depends on 7)

The crystalline form of ondansetron of claim 7 containing less than or equal to about 1% other crystalline forms of ondansetron.

### Claim 9 (depends on 1)

A pharmaceutical composition or dosage form comprising the crystalline form of ondansetron of claim 1 and at least one pharmaceutical excipient.

### Claim 10 (depends on 9)

The pharmaceutical composition or dosage form of claim 9 that is an orally disintegrating tablet.

### Claim 11 (depends on 1)

A method of treating nausea and vomiting in a patient comprising administering to the patient the crystalline form of ondansetron of claim 1.

### Claim 12 (depends on 1)

A process for preparing a crystalline form of ondansetron comprising:
a) dissolving ondansetron in an alcohol selected from the group consisting of methanol, ethanol, propan-1-ol and propan-2-ol,
b) crystallizing ondansetron from the alcohol under conditions effective to produce the crystalline form of ondansetron of claim 1, and
c) separating the crystalline form of ondansetron from the alcohol.

### Claim 13 (depends on 12)

The process of claim 12 wherein dissolving produces a clear solution.

### Claim 14 (depends on 13)

The process of claim 13 wherein the concentration of the solution is from about 50 mM to about 300 mM.

### Claim 15 (depends on 14)

The process of claim 14 wherein separating the crystalline form of ondansetron from the alcohol comprises filtering and drying to a loss on drying of about 2 wt. %.

### Claim 16 (depends on 1)

A process for preparing the crystalline form of ondansetron of claim 1 comprising:
a) mixing ondansetron and a predetermined amount of an alcohol selected from the group consisting of methanol, ethanol, propan-1-ol and propan-2-ol
b) forming a solution of the ondansetron in the alcohol by application of heat, wherein the predetermined amount of alcohol is selected to produce a solution with a concentration of from about 85 mM to about 150 mM solution,
c) crystallizing ondansetron from the solution by cooling the alcohol to from about 0° C. to about 20° C.
d) separating the ondansetron from the alcohol, and
e) drying.

### Claim 17 (depends on 16)

The process of claim 16 wherein forming the solution renders the alcohol free of visible suspended solids.

### Claim 18

A crystalline form of ondansetron characterized by a powder X-ray diffraction pattern having peaks at 25.4, 26.7 and 27.8±1.0 degrees two-theta.

### Claim 19 (depends on 18)

The crystalline form of ondansetron of claim 18 further characterized by strong intensity peaks in the powder X-ray diffraction pattern at 23.2, 25.9 and 27.8±1.0 degrees two-theta and medium intensity peaks at 25.4 and 26.7±1.0 degrees two-theta.

### Claim 20 (depends on 18)

The crystalline form of ondansetron of claim 18 further characterized by peaks in the powder X-ray diffraction pattern at 11.0, 14.8, 15.5, 16.4, 20.6, 21.4, 24.2±1.0 degrees two-theta.

### Claim 21 (depends on 18)

The crystalline form of ondansetron of claim 18 containing less than or equal to about 5% other crystalline forms of ondansetron.

### Claim 22 (depends on 21)

The crystalline form of ondansetron of claim 21 containing less than or equal to about 1% other crystalline forms of ondansetron.

### Claim 23 (depends on 18)

The crystalline form of ondansetron of claim 18 further characterized by a thermal analysis result indicative of a melting point of 230±2° C.

### Claim 24 (depends on 23)

The crystalline form of ondansetron of claim 23 wherein the thermal analysis result is a differential scanning calorimetry thermogram taken at a heating rate of 10° C. min−1 in a closed pan that exhibits a melting endotherm with a maximum at 230±2° C.

### Claim 25 (depends on 24)

The crystalline form of ondansetron of claim 24 wherein the melting endotherm has a magnitude of 324.26 Joules per gram.

### Claim 26 (depends on 18)

A pharmaceutical composition or dosage form comprising the crystalline form of ondansetron of claim 18 and at least one pharmaceutical excipient.

### Claim 27 (depends on 26)

The pharmaceutical composition or dosage form of claim 26 that is an orally disintegrating tablet.

### Claim 28 (depends on 18)

A method of treating nausea and vomiting in a patient comprising administering to the patient the crystalline form of ondansetron of claim 18.

### Claim 29 (depends on 18)

A process for preparing a crystalline form of ondansetron comprising:
a) dissolving ondansetron in a solvent system selected from the group consisting of organic solvents and mixtures of organic solvent and water, wherein the organic solvent is selected from the group consisting of mono-, di-, and polyhydroxylic alcohols containing four or more carbon atoms, liquid aromatic compounds, acetic acid ester and polar aprotic solvents,
b) crystallizing ondansetron form the alcohol under conditions effective to produce the crystalline form of ondansetron of claim 18, and
c) separating the crystalline form of ondansetron from the solvent.

### Claim 30 (depends on 29)

The process of claim 29 wherein the organic solvent is selected from the group consisting of 1-butanol, benzene, toluene, ethyl acetate, butyl acetate and DMF.

### Claim 31 (depends on 30)

The process of claim 30 wherein the organic solvent is selected from the group consisting of 1-butanol and DMF.

### Claim 32 (depends on 29)

The process of claim 29 wherein dissolving produces a clear solution.

### Claim 33 (depends on 32)

The process of claim 32 wherein the concentration of the solution is from about 50 mM to about 300 mM.

### Claim 34 (depends on 29)

The process of claim 29 wherein the dissolving includes heating a mixture of ondansetron and the solvent.

### Claim 35 (depends on 29)

The process of claim 29 wherein the crystallizing includes cooling the solution of ondansetron in the liquid medium.
